A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early

Inclusion Criteria:

* Written informed consent
* Female patients with breast cancer confirmed by histology.
* Tumour and blood samples according to APPENDIX I available.
* Age 18 years or older. Elderly patients in condition adequate for chemotherapy.
* Localized primary breast cancer including inflammatory breast cancer suitable for primary medical treatment and/or regional lymph node metastases including ipsilateral supraclavicular nodes with breast cancer diagnosis confirmed by histological examination with or without breast tumour lesions.
* Adequate bone marrow, renal, hepatic and cardiac functions and no other uncontrolled medical or psychiatric disorders.
* ECOG performance status 0-1.
* Patients in child-bearing age with adequate contraception.

Exclusion Criteria:

* Distant metastases, including node metastases in the contralateral breast region and in the mediastina.
* Other malignancy for the last two years except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix.
* HER2-amplification verified by FISH analysis.
* Pregnancy or lactation.
* Uncontrolled hypertension, heart, liver, kidney related or other medical or psychiatric disorders.
* Recent history of thromboembolism and ongoing medication with full-dose anticoagulants.
* Major surgery (including open biopsy), significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment.
* Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion.
* History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding.
* Non-healing wound, active peptic ulcer or bone fracture.
* History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrollment.